drugset / Trial / NCT00371124

Safety and Efficacy Study of 0.5%, 0.1% & 0.01% Atropine Treatment to Both Eyes In Treatment of Myopia In Children

NCT00371124

Phase 2/3 Unknown 400 enrolled Singapore National Eye Centre
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to find an optimal dose of atropine for preventing the rapid progression of myopia in children by comparing the efficacy, safety and functional impact of binocular treatment with 0.5%, 0.1% and 0.01% atropine and to develop a treatment regimen for the routine management of childhood myopia.

Timeline

Start
2006-03
Primary completion
Completion

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Atropine Other / unclassified 0.01 % Other
Subject Atropine Other / unclassified 0.1 % Other
Subject Atropine Other / unclassified 0.5 % Other

Indications